Sharmaine
This is an excellent article to give to your oncologist.
Its kinda of graphic, so if you have a weak stomache , you might selectively read jus the abstract and the conclusion.
http://www.ncbi.nlm.nih.gov/pmc/article ... 04-408.pdf
Cryosurgery for lung cancer
Lizhi Niu1,2, Kecheng Xu1,2, Feng Mu1,2
1Department of Oncology, Affiliated Fuda Hospital, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, No. 91-93
Judezhong Road, Haizhu District, Guangzhou 510305, China; 2Guangzhou Fuda Cancer Hospital, Jinan University School of Medicine, No. 2
Tangdexi Road, Tianhe District, Guangzhou 510305, China
ABSTRACT
Cryosurgery is suited for patients with lung cancer who are not considered for lung resection because of the advanced stage
of the disease or the patient’s poor general condition or poor respiratory function and with tumor recurrence following
radiotherapy, chemotherapy or lung resection, and those patients who have localized lung cancer but refuse to receive
operative therapy. Procedures of cryosurgery for lung cancer can be performed through endobronchial, direct intrathoracic
(at exploratory thoracotomy) or percutaneous routes depending upon location and size of tumor. Six hundred and twentyfive
patients with Non-small cell lung cancer (NSCLC) received percutaneous cryoablation in Fuda Cancer Hospital
Guangzhou, China. One hundred and fifty patients were followed-up for 12 to 38 months. Results showed that 1-, 2-, and
3-year survival rates were 64%, 45% and 32%, respectively. The adverse effects after cryosurgery of lung cancer include
haemoptysis, pneumothorax, bloody thorax, pleural effusion and pulmonary infection which are generally mild, transient,
and recovery with symptomatic management. In vitro studies have shown cryotherapy of lung cancer cells can improve the
immune system to trigger the specific anti-tumor response. In the future, comparative studies between this modality and
other therapies should be conducted for the treatment of lung cancer. In addition, more attention needs to be put on the
immunomodulators that enhance the cryoimmunology.
KEY WORDS Lung cancer; cryosurgery; cryoablation; cryotherapy; cryoimmunology
Conclusion
Percutaneous cryoablation offers an effective therapy for patients
with locally advanced non-small-cell lung cancer, without
serious complications. It is especially suitable for the treatment
of unresectable lung tumors (e.g., the cancer with multiple
nodules, large tumor and ill-located tumor) and for the cancer
patients with co-morbidity conditions considered to be poor
surgical candidates. The therapeutic efficacy of the procedure is
preponderate over that of routine chemotherapy and radiation.
In vitro studies have shown cryotherapy of lung cancer cells can
improve the immune system to trigger the specific anti-tumor
response. However, this study is still a preliminary one. In the
future, comparative studies between this modality and wedge
resection, stereotactic radiation or other therapies should be
conducted to further determine the efficacy and role of this
novel approach for the treatment of lung cancer. In addition,
more attention needs to be put on the immunomodulators that
enhance the cryoimmunology. Nevertheless, according to the
current data, percutaneous cryoablation, a feasible and miniinvasive
technique, has demonstrated an encouraging efficacy in
the treatment of advanced non-small-cell lung cancer.
Another article on ASPS--Indolent sarcoma
http://www.curesarcoma.org/patient-reso ... ypes/asps/